Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
A new Nevada pricing transparency law for diabetes drugs remains alive, disappointing pharmaceutical industry groups that wanted the law to be rescinded immediately ( Pharm. Research & Mfrs. of Am. v. Sandoval , 2017 BL 325250, D. Nev., Case No. 2:17-CV-2315 JCM (CWH), 9/14/17 ).
Judge James C. Mahan of the U.S. District Court for the District of Nevada declined an invitation from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) to kill the Nevada law outright. The court said the groups hadn’t shown they were entitled to immediate relief.
PhRMA and BIO are seeking to prevent the state from implementing the law, which requires drugmakers and pharmacy benefit managers (PBMs) to disclose pricing and rebate information for diabetes drugs. They sued the state over the law Sept. 1, claiming it violates the U.S. Constitution and runs afoul of trade secret and patent protection laws. Although the groups couldn’t secure instant action from the court, the court will hear oral argument Oct. 17.
BIO predicted the groups’ efforts to stop the law from being implemented would ultimately succeed. “BIO remains confident in the eventual outcome of the process,” George Goodno, BIO’s communications director for state policy, international affairs and intellectual property, told Bloomberg BNA Sept. 15. Similarly, PhRMA said in a Sept. 15 statement it looks forward to arguing the case for enjoining the law at the October hearing.
If the law stays on the books, the groups warn it would cause massive disinvestment in the pharma and biotech industries. The law became effective this summer but hasn’t yet been implemented.
In his Sept. 14 order denying the groups’ bid to immediately enjoin the law, Mahan said the groups didn’t demonstrate they would suffer immediate and irreparable injury, loss, or damage if the court gave the state of Nevada time to respond before the court makes a decision on the law’s fate.
The state’s response is due Sept. 27, with PhRMA and BIO’s reply due two weeks later, followed by the court hearing Oct. 17.
To contact the reporter on this story: Dana A. Elfin in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
The order is available at http://src.bna.com/szL.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)